1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
2. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–366.
3. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169(2):361–371.
4. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2281.
5. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(6):804–834.
6. Faes S, Demartines N, Dormond O. Resistance to mTORC1 inhibitors in cancer therapy: from kinase mutations to intratu- moral heterogeneity of kinase activity. Oxid Med Cell Longev. 2017;2017:1726078.
7. Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibi- tor resistance in cancer therapy. Target Oncol. 2011;6(1):17–27.
8. Rodrik-Outmezguine VS, Okaniwa M, Yao Z, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibi- tor. Nature. 2016;534(7606):272–276.
9. O'Reilly KE, Rojo F, She Q-B, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500–1508.
10. Carracedo A, Ma LI, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K- dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065–3074.
11. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogene- ity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892.
12. Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013.
13. ter Brugge P, Kristel P, van der Burg E, et al. Mechanisms of therapy resistance in patient-derived xenograft mod- els of BRCA1-deficient breast cancer. J Natl Cancer Inst. 2016;108(11):djw148.
14. Sivanand S, Pena-Llopis S, Zhao H, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med. 2012;4(137):137ra75.
15. Izumchenko E, Paz K, Ciznadija D, et al. Patient-derived xeno- grafts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol. 2017;28(10):2595–2605.
16. Jiménez-Valerio G, Martínez-Lozano M, Bassani N, et al. Resistance to antiangiogenic therapies by metabolic symbi- osis in renal cell carcinoma PDX models and patients. Cell Rep. 2016;15(6):1134–1143.
17. Diaz-Montero CM, Mao FJ, Barnard J, et al. MEK inhibition abro- gates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Br J Cancer. 2016;115(8):920–928.
18. Shibasaki N, Yamasaki T, Kanno T, et al. Role of IL13RA2 in sunitinib resistance in clear cell renal cell carcinoma. PLoS One. 2015;10(6):e0130980.
19. Bailey ST, Zhou B, Damrauer JS, et al. mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. PLoS One. 2014;9(9):e104413.
20. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 in- hibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia. 2006;8(5):394–401.
21. deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res. 2004;10(23):8059–8067.
22. Okegawa T, Morimoto M, Nishizawa S, et al. Intratumor heteroge- neity in primary kidney cancer revealed by metabolic profiling of multiple spatially separated samples within tumors. EBioMedicine. 2017;19:31–38.
23. Sakamoto H, Yamasaki T, Sumiyoshi T, et al. A family case with germline TSC1 and mtDNA mutations developing bilat- eral eosinophilic chromophobe renal cell carcinomas without other typical phenotype of tuberous sclerosis. J Clin Pathol. 2018;71(10):936–943.
24. Rogers MF, Shihab HA, Mort M, Cooper DN, Gaunt TR, Campbell C. FATHMM-XF: accurate prediction of pathogenic point muta- tions via extended features. Bioinformatics. 2018;34(3):511–513.
25. Shen Y, Takahashi M, Byun H-M, et al. Boswellic acid induces epigenetic alterations by modulating DNA methylation in colorec- tal cancer cells. Cancer Biol Ther. 2012;13(7):542–552.
26. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281–2308.
27. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. Evaluation of the infinium methylation 450K technology. Epigenomics. 2011;3(6):771–784.
28. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404.
29. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of com- plex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl.
30. Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352):eaan2507.
31. Arakaki R, Yamasaki T, Kanno T, et al. CCL2 as a potential ther- apeutic target for clear cell renal cell carcinoma. Cancer Med. 2016;5(10):2920–2933.
32. Song J, Rechkoblit O, Bestor TH, Patel DJ. Structure of DNMT1- DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science. 2011;331(6020):1036–1040.
33. Takeshita K, Suetake I, Yamashita E, et al. Structural insight into maintenance methylation by mouse DNA methyltransfer- ase 1 (Dnmt1). Proc Natl Acad Sci USA. 2011;108(22):9055– 9059.
34. Zhang H, Berel D, Wang Y, et al. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsiroli- mus in preclinical renal cell carcinoma models. PLoS One. 2013;8(1):e54918.
35. Ruiz de Garibay G, Mateo F, Stradella A, et al. Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance. Dis Model Mech. 2018;11(5):dmm032292.
36. Xu Y, Zhang F, Pan X, et al. Xenograft tumors derived from ma- lignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance. Cancer Commun. 2018;38(1):19.
37. Zarrizi R, Menard JA, Belting M, Massoumi R. Deubiquitination of gamma-tubulin by BAP1 prevents chromosome instability in breast cancer cells. Cancer Res. 2014;74(22):6499–6508.
38. Hsieh JJ, Chen D, Wang PI, et al. Genomic biomarkers of a randomized trial comparing first-line everolimus and suni- tinib in patients with metastatic renal cell carcinoma. Eur Urol. 2017;71(3):405–414.
39. Wagle N, Grabiner BC, Van Allen EM, et al. Response and ac- quired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426–1433.
40. Hamieh L, Choueiri TK, Ogórek B, et al. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet. 2018;14(9):e1007679.
41. Koh KX, Tan GH, Hui Low SH, et al. Acquired resistance to PI3K/ mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis. Oncotarget. 2017;8(66):110133–110144.
42. Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19(2):81–92.
43. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 1992;69(6):915–926.
44. Fan G, Beard C, Chen RZ, et al. DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. J Neurosci. 2001;21(3):788–797.
45. Klein CJ, Botuyan M-V, Wu Y, et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet. 2011;43(6):595–600.
46. Sheaffer KL, Elliott EN, Kaestner KH. DNA hypomethylation contributes to genomic instability and intestinal cancer initiation. Cancer Prev Res. 2016;9(7):534–546.
47. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49.
48. Lee E, Wang J, Yumoto K, et al. DNMT1 regulates epithelial-mes- enchymal transition and cancer stem cells, which promotes pros- tate cancer metastasis. Neoplasia. 2016;18(9):553–566.
49. Byers LA, Diao L, Wang J, et al. An epithelial-mesenchy- mal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19(1):279–290.
50. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–629.
51. Bai R, Li D, Shi Z, Fang X, Ge W, Zheng S. Clinical significance of Ankyrin repeat domain 12 expression in colorectal cancer. J Exp Clin Cancer Res. 2013;32(1):35.
52. Thomas LN, Chedrawe ER, Barnes PJ, Too CKL. Prolactin/an- drogen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro. Breast Cancer Res Treat. 2017;164(1):27–40.
53. Marin I. Ancient origin of animal U-box ubiquitin ligases. BMC Evol Biol. 2010;10:331.
54. Qi D, Wang M, Yu F. Knockdown of lncRNA-H19 inhibits cell viability, migration and invasion while promotes apopto- sis via microRNA-143/RUNX2 axis in retinoblastoma. Biomed Pharmacother. 2019;109:798–805.
55. Wu ZR, Yan L, Liu YT, et al. Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tu- mours. Nat Commun. 2018;9(1):4624.
56. Li Y, Wang X. The role of cullin4B in human cancers. Exp Hematol Oncol. 2017;6:17.
57. He YM, Xiao YS, Wei L, Zhang JQ, Peng CH. CUL4B promotes metastasis and proliferation in pancreatic cancer cells by inducing epithelial-mesenchymal transition via the Wnt/beta-catenin signal- ing pathway. J Cell Biochem. 2018;119(7):5308–5323.
58. Ghosh P, Wu M, Zhang H, Sun H. mTORC1 signaling requires proteasomal function and the involvement of CUL4-DDB1 ubiqui- tin E3 ligase. Cell Cycle. 2008;7(3):373–381.
59. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2009;29(6):1411–1420.
60. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res. 2003;1(11):789–800.
61. Foster DA, Salloum D, Menon D, Frias MA. Phospholipase D and the maintenance of phosphatidic acid levels for regula- tion of mammalian target of rapamycin (mTOR). J Biol Chem. 2014;289(33):22583–22588.
62. Lawrence RE, Cho KF, Rappold R, et al. A nutrient-induced affinity switch controls mTORC1 activation by its Rag GTPase-Ragulator lysosomal scaffold. Nat Cell Biol. 2018;20(9):1052–1063.
63. Okosun J, Wolfson RL, Wang J, et al. Recurrent mTORC1-acti- vating RRAGC mutations in follicular lymphoma. Nat Genet. 2016;48(2):183–188.
64. Nguyen TP, Frank AR, Jewell JL. Amino acid and small GTPase regulation of mTORC1. Cell Logist. 2017;7(4):e1378794.
65. Rozengurt E, Soares HP, Sinnet-Smith J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther. 2014;13(11):2477–2488.
66. Duarte AA, Gogola E, Sachs N, et al. BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. Nat Methods. 2018;15(2):134–140.